Skip to main content

Rheumatoid Arthritis

      Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias. At EULAR 2023 in Milan, the perfect platform was provided for an airing of grievances, in a debate entitled ‘Clinically suspect arthralgias: fact or myth’.
      RA and cancer risk in the biologic era

      RA is known to be historically associated with site specific cancers, especiall

      Dr. John Cush RheumNow

      2 years ago
      RA and cancer risk in the biologic era RA is known to be historically associated with site specific cancers, especially lung skin and lymphomas. This risk was described as likely to be supported by chronic systemic inflammation before the biologic era. https://t.co/4Pe6SIS6yb https://t.co/e2enjkXoly
      AI in RA: the story grows along the patient pathway

      The use of AI to analyse large data sets using its subset componen

      Dr. John Cush RheumNow

      2 years ago
      AI in RA: the story grows along the patient pathway The use of AI to analyse large data sets using its subset component machine learning (ML) has taken centre stage recently in the management of rheumatic conditions including RA. https://t.co/Jv4dmV2tlU https://t.co/KkgW0cD1QM
      RT @synovialjoints: EULAR 2023 recommendations on the management of fatigue in IRMDs. 4 overarching principles and 4 rec

      Dr. Antoni Chan synovialjoints

      2 years ago
      EULAR 2023 recommendations on the management of fatigue in IRMDs. 4 overarching principles and 4 recommendations for monitoring and assessment of fatigue, Dures E Abst#P0370 #EULAR2023 @RheumNow https://t.co/AirPlRLNjZ
      RT @synovialjoints: The course of symptoms in CSA to RA showed greater severity in the ACPA+ group compared to the ACPA-

      Dr. Antoni Chan synovialjoints

      2 years ago
      The course of symptoms in CSA to RA showed greater severity in the ACPA+ group compared to the ACPA- group. This correlated with MRI-subclinical joint score, suggesting different underlying processes Khidir S Abst#POS319 #EULAR2023 @RheumNow https://t.co/C2ADAkkSM2
      T cells are known to play a key role in RA pathogenesis and the diversity of the T cell repertoire is known to be reduced in RA. 
      RT @bella_mehta: JaL1/TYK2 inhibitor vs Tofacitinib in #RA at #EULAR2023 phase 2. @RheumNow https://t.co/0F3JQ9dVMA

      Bella Mehta bella_mehta

      2 years ago
      JaL1/TYK2 inhibitor vs Tofacitinib in #RA at #EULAR2023 phase 2. @RheumNow https://t.co/0F3JQ9dVMA
      RT @bella_mehta: Abstracts talking about #RA and JAKs and Biologic comparisons
      Huge number of pts to analyze this aftrr

      Bella Mehta bella_mehta

      2 years ago
      Abstracts talking about #RA and JAKs and Biologic comparisons Huge number of pts to analyze this aftrr the initial NEJM study. Abstract summary pics below @RheumNow https://t.co/jl5S4fLq19
      RT @bella_mehta: Abatacept in pts at risk of #RA data from clinical trial.
      213 pts, 31 centers.
      Pts with multiple autoa

      Bella Mehta bella_mehta

      2 years ago
      Abatacept in pts at risk of #RA data from clinical trial. 213 pts, 31 centers. Pts with multiple autoantibodies improved the most with abatacept. @rheumnow #EULAR2023 https://t.co/c82jx0cAEq
      ×